Search results
Remdesivir has no significant effect on patients with COVID-19 who are already being ventilated. Among other hospitalised patients, it has a small effect against death or progression to ventilation (or both).
Najważniejsze informacje. • U dorosłych hospitalizowanych z powodu COVID-19, stosowanie remdesiwiru, w porównaniu z placebo (leczeniem pozorowanym) lub standardową opieką, ma prawdopodobnie niewielki lub żaden wpływ na ryzyko zgonu w ciągu 150 dni od rozpoczęcia leczenia.
22 gru 2021 · A 3-day course of remdesivir had an acceptable safety profile and prevented disease progression resulting in hospitalization among high-risk patients with Covid-19.
21 lut 2023 · Since the outbreak of the COVID-19 pandemic, immense efforts have been made to find effective treatments for the disease. 1–3 The broad-spectrum antiviral medication remdesivir was identified as a promising therapeutic candidate because of its ability to inhibit coronaviruses in vitro—including SARS-CoV-2, which causes COVID-19. 4–6 For ...
27 maj 2020 · Patients were randomly assigned in a 1:1 ratio to receive intravenous remdesivir for either 5 days or 10 days. All patients received 200 mg of remdesivir on day 1 and 100 mg once daily on ...
9 sie 2023 · Remdesivir, provided to adult patients hospitalized for COVID-19-associated pneumonia as a 10-day or 5-day course, shortens the recovery time and allows for early clinical improvement, according to phase 3 studies.
21 maj 2022 · Despite 2 years having passed since the start of the COVID-19 pandemic, there is still intense debate about the best therapeutic strategy for patients with COVID-19. Multiple randomised studies have evaluated the efficacy of different antiviral,1,2 anti-inflammatory, and antithrombotic treatments.
